552c7ae14ClaimGeraldine Levano reached more than three years of cancer remission following her stage 3 colorectal cancer treatments.AgreeDisagree
552c7ae14ClaimRadon is the second leading cause of lung cancer after smoking, causing an estimated 21,000 deaths annuallyAgreeDisagree
552c7ae14ClaimMass General Brigham Cancer Institute will offer services across eight cancer specialties, including gastrointestinal and thoracic oncology, by November 2026, MGB saidAgreeDisagree
552c7ae14ClaimIn the Sungkyunkwan University cohort, each 1-unit increase in biological age acceleration based on nine routine blood markers was associated with a 7% higher risk of early-onset colorectal adenocarcinoma.AgreeDisagree
552c7ae14ClaimThe original version of Freenome's blood-based SimpleScreen CRC screening test is already FDA-approved for colorectal cancer surveillance.AgreeDisagree
552c7ae14ClaimA study found advanced stage at diagnosis accounted for 24.9% of excess rural breast cancer deaths, while radiation omission and chemotherapy omission accounted for 11.4% and 7.9% respectively.AgreeDisagree
552c7ae14ClaimThe American College of Obstetricians and Gynecologists guidelines recommend systemic hormone replacement therapy with estrogen and progestogen for women with a uterus to mitigate endometrial cancer risk from estrogen-stimulated uterine lining growth, or estrogen alone withoutAgreeDisagree
552c7ae14ClaimSatralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signalingAgreeDisagree
552c7ae14ClaimThyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidismAgreeDisagree
552c7ae14ClaimSatralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye diseaseAgreeDisagree
552c7ae14ClaimPrior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026AgreeDisagree
552c7ae14ClaimSatralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory conditionAgreeDisagree
552c7ae14ClaimSatralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare providerAgreeDisagree
552c7ae14ClaimAlthough satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2AgreeDisagree
552c7ae14ClaimOn October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye diseaseAgreeDisagree
552c7ae14ClaimThe FDA approval of satralizumab for thyroid eye disease was based on data from the global phase 3 SatraGO program, which enrolled 258 patients across 19 countriesAgreeDisagree
552c7ae14ClaimIn satralizumab's phase 3 SatraGO-2 trial of active thyroid eye disease, 52.9% of satralizumab patients achieved a proptosis response of at least 2 mm reduction (vs. 23.4% placebo) and 60.7% achieved diplopia reduction (vs. 25.8% placebo)AgreeDisagree
552c7ae14ClaimRoche is studying satralizumab in additional neurologic, autoimmune, and inflammatory conditions that may benefit from interleukin-6 signaling inhibitionAgreeDisagree